Pharmamarketeer

Celgene’s Inrebic becomes second FDA-approved therapy for rare bone marrow disorder

Celgene is celebrating the approval in the US of its Janus kinase (JAK) 2 inhibitor Inrebic (fedratinib) in the treatment of intermediate-2 or high-risk primary or secondary myelofibrosis, a rare disorder of the bone marrow.

A chronic condition, myelofibrosis is characterised by the formation of scar tissue in the bone marrow, disrupting the production of blood cells and leading to severe anaemia and the enlargement of the body’s organs.

read more

Advertentie(s)
Geen nieuws missen?
Volg de duizenden farma professionals die Pharmamarkteer.nl via e-mail lezen

Uw inschrijving is gelukt.
Bedankt!
Naar Pharmamarkteer.nl